US EditionOne Dose of RSV Vaccine May Shield Older People for Two Seasons
The RSVpreF vaccine lowered all-cause cardiorespiratory hospitalizations by 9.9% in adults aged 60+, with similar effects regardless of cardiovascular disease history, researchers found.
- Researchers reported on August 30, 2025, that a single dose of RSV vaccine reduced hospitalization risk by 58% among seniors during two RSV seasons.
- This finding followed trials showing RSVpreF vaccination lowered all-cause cardiorespiratory hospitalizations in adults 60 and older, while vaccine effectiveness waned over time.
- The randomized clinical trial included over 131,000 adults with a mean age of 69.4 years in Denmark during the 2024–2025 winter season, monitoring 7,000 hospitalized older adults at 26 U.S. hospitals.
- Dr. Wesley Self highlighted that the findings provide strong evidence that RSV vaccines reduce hospital admissions and severe illness, and he stressed the importance of ongoing monitoring to inform potential booster dose recommendations.
- The study suggests vaccination reduces severe RSV outcomes in older adults but raises questions about dosing intervals, indicating guidelines may require review to maintain protection.
Insights by Ground AI
Does this summary seem wrong?
23 Articles
23 Articles
ABC FOX Montana+21 Reposted by 21 other sources
One Dose of RSV Vaccine May Shield Older People for Two Seasons
Key Takeaways
·Missoula, United States
Read Full Article
Coverage Details
Total News Sources23
Leaning Left4Leaning Right2Center4Last UpdatedBias Distribution40% Left, 40% Center
Bias Distribution
- 40% of the sources lean Left, 40% of the sources are Center
40% Center
L 40%
C 40%
R 20%
Factuality
To view factuality data please Upgrade to Premium
